Gain Therapeutics Inc (GANX) - Total Assets
Based on the latest financial reports, Gain Therapeutics Inc (GANX) holds total assets worth $10.97 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GANX total equity for net asset value and shareholders' equity analysis.
Gain Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Gain Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Gain Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Gain Therapeutics Inc's total assets of $10.97 Million consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.7% |
| Accounts Receivable | $765.76K | 6.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $134.27K | 1.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Gain Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gain Therapeutics Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gain Therapeutics Inc's current assets represent 95.7% of total assets in 2024, an increase from 60.9% in 2018.
- Cash Position: Cash and equivalents constituted 85.7% of total assets in 2024, up from 49.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 6.3% of total assets.
Gain Therapeutics Inc Competitors by Total Assets
Key competitors of Gain Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Gain Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.52 | 2.99 | 4.25 |
| Quick Ratio | 2.52 | 2.99 | 4.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.35 Million | $9.15 Million | $6.87 Million |
Gain Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Gain Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.90 |
| Latest Market Cap to Assets Ratio | 5.96 |
| Asset Growth Rate (YoY) | -34.9% |
| Total Assets | $12.12 Million |
| Market Capitalization | $72.31 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Gain Therapeutics Inc's assets at a significant premium (5.96x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Gain Therapeutics Inc's assets decreased by 34.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Gain Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Gain Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $12.12 Million | -34.85% |
| 2023-12-31 | $18.61 Million | -22.78% |
| 2022-12-31 | $24.10 Million | -38.18% |
| 2021-12-31 | $38.99 Million | +305.91% |
| 2020-12-31 | $9.60 Million | +1354.58% |
| 2019-12-31 | $660.29K | -18.65% |
| 2018-12-31 | $811.63K | -- |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the … Read more